Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 13/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675623 | 0.92 | HSD11B1 (0.35) | IDH1HSD11B1HRH3P2RX7 | |
| SCHEMBL13674510 | 0.84 | ALDH1A1 (0.38) | P2RX7 | |
| SCHEMBL13674485 | 0.83 | OPRM1 (0.39) | HSD11B1P2RX7 | |
| SCHEMBL4510197 | 0.83 | OPRM1 (0.39) | HSD11B1P2RX7 | |
| SCHEMBL13674513 | 0.83 | HSD11B1 (0.40) | HSD11B1P2RX7 | |
| SCHEMBL13674486 | 0.82 | P2RX7 (0.42) | HSD11B1P2RX7 | |
| SCHEMBL3001590 | 0.82 | P2RX7 (0.42) | HSD11B1P2RX7 | |
| SCHEMBL3001587 | 0.82 | P2RX7 (0.42) | HSD11B1P2RX7 | |
| SCHEMBL3001594 | 0.82 | P2RX7 (0.42) | HSD11B1P2RX7 | |
| SCHEMBL4502408 | 0.81 | HSD11B1 (0.39) | HSD11B1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | IDH1 278/4885HSD11B1 1/4885HRH3 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.